Interaction Checker

Interaksi Irinotekan

Irinotekan (Camptosar, Onivyde) memiliki 137 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 113 mayor, 21 moderat, 2 minor, dan 1 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (113)

  • Amiloriddiuretik hemat kaliumMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • AmiodaronantiaritmiaMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Asam etakrinatdiuretik loopMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Asetazolamidpenghambat karbonat anhidraseMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • AtazanavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Atenolol dan klortalidonpenyekat betaMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • AtropinantikolinergikMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Atropin dan pralidoksimantikolinergikMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Benazepril dan hidroklorotiazidpenghambat ACEMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Betanekolagonis kolinergikMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • BisakodilpencaharMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Bosentanpenginduksi CYP3A4Mayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Bumetaniddiuretik loopMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • DarunavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Difenoksilat dan atropinMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Difenoksin dan atropinMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Diltiazempenghambat kanal kalsiumMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • DokusatpencaharMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • DronedaronantiaritmiaMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • EfavirenzantiretroviralMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Enalapril dan hidroklorotiazidpenghambat ACEMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Eplerenonantagonis aldosteronMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Eritromisinantibiotik makrolidaMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • EtravirinantiretroviralMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • EverolimusimunosupresanMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • FenitoinantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • FenobarbitalbarbituratMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Fenobarbital, hiosiamin, atropin, dan skopolaminbarbituratMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Fentermin dan topiramatstimulan SSPMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Flukonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Fosinopril dan hidroklorotiazidpenghambat ACEMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Furosemiddiuretik loopMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • GriseofulvinantijamurMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Hidroklorotiaziddiuretik tiazidMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Imatinibpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Indapamiddiuretik tiazidMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • IsoniazidantibiotikMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • KarbamazepinantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • KlobazambenzodiazepinMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Klorotiaziddiuretik tiazidMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • LaktulosapencaharMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • LenakapavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Loperamidobat yang memperpanjang interval QTMayor

    Late diarrhea can be life threatening and should be treated promptly with loperamide. (label Irinotekan, Peringatan kotak hitam)

  • Lopinavir dan ritonavirantiretroviralMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Metolazondiuretik tiazidMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Mifepristonpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Modafinilstimulan SSPMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • NefazodonantidepresanMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • NevirapinantiretroviralMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Palbosiklibpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • PerampanelantikonvulsanMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Pilokarpinagonis kolinergikMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Piridostigminpenghambat kolinesteraseMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Polietilen glikol 3350pencaharMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Posakonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • PrimidonantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • RifabutinantibiotikMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • RifampisinantibiotikMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • RifapentinantibiotikMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • RitonavirantiretroviralMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Senna (senosida)pencaharMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • SenobamatantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Sevimelinagonis kolinergikMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • SiklosporinimunosupresanMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • SkopolaminantikolinergikMayor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (label Irinotekan, Peringatan kotak hitam)

  • Sofosbuvir dan velpatasvirantivirusMayor

    Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (label Sofosbuvir dan velpatasvir, Interaksi obat)

  • Spironolaktonantagonis aldosteronMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Suvoreksantsedatif-hipnotikMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • TikagrelorantiplateletMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • TopiramatantikonvulsanMayor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Torasemiddiuretik loopMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumMayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (label Irinotekan, Interaksi obat)

Interaksi moderat (21)

  • Asam valproatantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • BrivarasetamantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • Divalproeks (valproat)antikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • Eltrombopagpenghambat OATP1B1Moderat

    …(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (label Eltrombopag, Interaksi obat)

  • EtosuksimidantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • FelbamatantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • GabapentinantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • GemfibrozilfibratModerat

    Coadministration of CAMPTOSAR with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irinotecan or SN-38. (label Irinotekan, Interaksi obat)

  • Kanabidiol (obat resep)antikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • KapesitabinantimetabolitModerat

    Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (label Kapesitabin, Interaksi obat)

  • KlonazepambenzodiazepinModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • LakosamidantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • LamotriginantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • LevetirasetamantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • MetsuksimidantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • PregabalinantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • Rolapitantpenghambat CYP2D6Moderat

    BCRP Substrates with a Narrow Therapeutic Index (e.g., methotrexate, topotecan, or irinotecan) Clinical Impact: Increased plasma concentrations of BCRP substrates (e.g., methotrexate, topotecan, or irinotecan) may result in potential adverse reactions [see Clinical Pharmacology (12.3) ]. (label Rolapitant, Interaksi obat)

  • RufinamidantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • TiagabinantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • VigabatrinantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

  • ZonisamidantikonvulsanModerat

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (label Irinotekan, Interaksi obat)

Penyebutan minor (2)

  • FluorourasilantimetabolitMinor

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (label Irinotekan, Interaksi obat)

  • LeukovorinMinor

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (label Irinotekan, Interaksi obat)

Tidak ada interaksi bermakna yang dilaporkan (1)

  • BevasizumabTanpa interaksi

    Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (label Bevasizumab, Interaksi obat)

Periksa Irinotekan terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.